In a May 18 op-ed for the Financial Times, Louise Richardson, Vice-Chancellor of the University of Oxford and CEU Board Trustee, calls for vaccine makers to follow the lead of Oxford and AstraZeneca, and deploy vaccines swiftly, globally and affordably.
Emphasizing that no one should profiteer from a pandemic, Richardson tells other drug-makers to waive intellectual property rights and to work with partners committed to producing and distributing vaccines at cost.
“Now is the time for other companies — especially those deriving enormous profits from the pandemic — to play their part. Rather than charge $20 per jab, they should financially support Covax, share their vaccine and the means to distribute it, and contribute to the development of infrastructure in low- and middle-income countries,” she concludes.
From the beginning of development, Oxford and AstraZeneca agreed to operate on a not-for-profit basis for the duration of the coronavirus pandemic, requiring only the costs of production and distribution to be covered. These conditions, set out by the Vice-Chancellor during her recent appearance at CEU’s Presidential Lecture, illustrate the significance of the university's role in shaping the uses of sciences to achieve social benefits.
To read the full op-ed, visit here (subscription required).